MedTrace Logo

FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients

NCT02935764 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2016-10-17

No results posted yet for this study

Summary

This study is designed to compare the efficacy and safety of FOLFIRI regimen with irinotecan monodrug in the treatment of advanced colorectal cancer patients in the second-line setting.

Conditions

  • Colorectal Carcinoma

Interventions

DRUG

Irinotecan

180 mg/m2 iv gtt, d1

DRUG

5-fluorouracil

5-FU 400mg/m2 iv, 2400mg/m2 civ 46h

DRUG

Leucovorin

400mg/m2 iv gtt,d1

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2019-10-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02935764 on ClinicalTrials.gov